NOVARTIS AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.74 USD | +0.47% |
|
+4.78% | -3.41% |
| 10:18am | Novartis: positive data for malaria treatment | CF |
| 09:26am | NOVARTIS AG : JP Morgan remains Neutral | ZD |
Financials (USD)
| Sales 2024 * | 48.66B | Sales 2025 * | 50.44B | Capitalization | 199B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.23B | Net income 2025 * | 11.85B | EV / Sales 2024 * | 4.35 x |
| Net Debt 2024 * | 12.19B | Net Debt 2025 * | 10.31B | EV / Sales 2025 * | 4.16 x |
| P/E ratio 2024 * |
19.5
x | P/E ratio 2025 * |
16.7
x | Employees | 76,057 |
| Yield 2024 * |
3.68% | Yield 2025 * |
3.87% | Free-Float | 81.95% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novartis AG
More press releases
| 1 day | +2.27% | ||
| 1 week | +4.38% | ||
| Current month | +0.57% | ||
| 1 month | +1.09% | ||
| 3 months | -9.70% | ||
| 6 months | +2.74% | ||
| Current year | -3.65% |
1 week
92.35
99.50
1 month
92.3599.50
Current year
92.35108.78
1 year
92.19108.78
3 years
74.09108.78
5 years
69.18108.78
10 years
66.93108.78
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 04-12-31 | |
| Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
| Chairman | 68 | 12-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 8.01% | 13 M€ | -.--% | ||
| 1.52% | 9 M€ | -4.31% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 97.61 | +0.34% | 970 293 |
| 24-04-23 | 97.28 | +2.27% | 3,837,430 |
| 24-04-22 | 95.12 | +0.81% | 2,447,775 |
| 24-04-19 | 94.36 | +1.93% | 2,338,264 |
| 24-04-18 | 92.57 | -0.55% | 1,054,610 |
Delayed Quote Nyse, April 23, 2024 at 04:00 pm EDT
More quotes
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
97.67
USD
Average target price
107.6
USD
Spread / Average Target
+10.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.92% | 672B | |
| +27.07% | 570B | |
| -4.59% | 360B | |
| +16.38% | 321B | |
| +9.39% | 300B | |
| +7.40% | 217B | |
| -8.71% | 204B | |
| -8.58% | 149B | |
| -4.99% | 147B |
- Stock Market
- Equities
- NOVN Stock
- NVS Stock
